1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Physician Views: The return of inhaled insulin – a paradigm shift or hard sell?

Physician Views: The return of inhaled insulin – a paradigm shift or hard sell?

  • February 2015
  • ID: 2802265
  • Format: PDF
  • By Firstword Pharma

Summary






Sanofi is currently in the process of launching Afrezza in the US market. Afrezza is an inhaled insulin developed by MannKind, which was in-licensed by Sanofi last year. It is the first inhaled insulin to be made available since Pfizer launched Exubera in the US in September 2006. Due to poor uptake, Exubera was withdrawn from the market in October 2007.

Both Exubera and Afrezza have demonstrated comparable, but not superior, efficacy to injectable insulin. Commercial failure of Pfizer's product was driven in part by additional cost (for the patient/payer) and the large inconvenient device that was used to administer Exubera.

MannKind and Sanofi have sought to circumvent these issues: Afrezza is delivered via a small, whistle-sized device and has a list price of between $225 and $280 for a 30-day supply of 90 cartridges. Assuming a typical level of rebates and discounts, analysts do not expect this price to act as a major obstacle to access.

Challenges are nevertheless expected to lie ahead. These include likely broad tier-3 formulary status at launch and the view among some analysts that endocrinologists will not proactively prescribe Afrezza, but instead wait for patients to request the drug (which in turn will increase necessary investment in promotion of the franchise).

When FirstWord polled 52 endocrinologists last April (shortly after Afrezza had gained a positive Advisory Committee recommendation), a key concern among physicians was the side-effect risk associated with inhalation. Around half of all respondents indicated that potential long-term pulmonary and cancer risks – an issue also discussed in depth during the AdCom – would act as the main reason for them not using Afrezza. Around a third of endocrinologists suggested that a likely lack of real-world efficacy versus injectable insulin would act as the main deterrent.

Sanofi's launch strategy for Afrezza is focused on two groups of diabetes patients: Those who are potential insulin users who do not currently use insulin because of a dislike of injections and those who use basal insulin, but are naïve to short-acting insulin and require an 'intensification' of therapy at mealtimes.

Patient feedback cited by Sanofi in recent investor presentations indicates a potentially sizeable population who are discouraged to initiate insulin therapy due to injectable administration, while physician feedback sourced by FirstWord indicates that patients with needle phobia represent the obvious target for Afrezza.

While Sanofi suggests that around 40 percent of potential insulin users are not using insulin because of a dislike of injections, translating this into an 'actionable' driver for uptake of Afrezza will nevertheless be challenging. Not only does anecdotal evidence indicate that many patients who are initially cautious towards self-injection quickly become adept at the practice, but the proportion of true needle-phobic patients is much lower.

With physicians already indicating that patients who are adverse to the idea of injection are likely to act as the most prominent users of Afrezza, it also remains to be seen how much traction Sanofi can achieve in those patients who need an intensification of therapy, but whom already inject basal insulin.








To better ascertain how the initial launch of Afrezza is likely to progress, and whether Sanofi's strategy appears feasible, FirstWord is polling US and EU-5 based endocrinologists this week (Sanofi is due to submit the drug for approval in Europe shortly). Specifically we are asking them…


Versus your experience in the real-world setting, what is your assessment of the suggestion that there are a significant proportion of potential insulin users – 40 percent – who are not currently using insulin because of a dislike of injections?
This figure is very low
This figure is moderately low
This figure is marginally low
This figure is accurate
This figure is marginally high
This figure is moderately high
This figure is very high

Is it fair to suggest that the majority of patients who are initially sceptical of self-injecting insulin quickly become adept at the practice?
Completely disagree
Disagree
Somewhat disagree
Neither agree or disagree
Somewhat agree
Agree
Completely agree

Patients who already self-inject basal insulin, but who require intensification with a short-acting insulin at mealtimes, represent a significant opportunity for use of Afrezza?
Completely disagree
Disagree
Somewhat disagree
Neither agree or disagree
Somewhat agree
Agree
Completely agree

Do you plan to actively prescribe Afrezza unless a patient specifically requests it?
No – will not prescribe under any circumstances
No – would recommend against prescribing
No – would prescribe readily if patient requests
Yes – slight use
Yes – moderate use
Yes – very high use
Yes – Extremely high use

Afrezza meets a significant unmet need in the insulin market?
Completely disagree
Disagree
Somewhat disagree
Neither agree or disagree
Somewhat agree
Agree
Completely agree


Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Phosphatase Non Receptor Type 1 - Pipeline Review, H2 2019

Tyrosine Protein Phosphatase Non Receptor Type 1 - Pipeline Review, H2 2019

  • $ 3500
  • December 2019

Tyrosine Protein Phosphatase Non Receptor Type 1 - Pipeline Review, H2 2019SummaryTyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental ...

 Insulin Resistance - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020

 Insulin Resistance - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020

  • $ 2000
  • January 2020

" Insulin Resistance - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020" report offers comprehensive insights on marketed and Phase III products for  Insulin Resistance. The marketed ...

Hyperinsulinemia - Pipeline Review, H2 2019

Hyperinsulinemia - Pipeline Review, H2 2019

  • $ 2000
  • December 2019

Hyperinsulinemia - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Hyperinsulinemia - Pipeline Review, H2 2019, provides an overview of the Hyperinsulinemia ...

Non-injectable Insulin $ 3950 January 2020

Bio Industry Markets in China $ 4000 October 2019


ref:plp2015

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on